Townsend & Associates’s Edwards Lifesciences EW Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$17.9M Buy
206,533
+3,132
+2% +$278K 1.51% 29
2026
Q2
$17.3M Buy
203,401
+3,935
+2% +$330K 1.47% 27
2026
Q1
$16.3M Buy
199,466
+5,809
+3% +$479K 1.4% 31
2025
Q4
$16.4M Buy
193,657
+3,323
+2% +$273K 1.46% 29
2025
Q3
$14.2M Buy
190,334
+6,158
+3% +$481K 1.35% 34
2025
Q2
$14.7M Sell
184,176
-30,623
-14% -$2.28M 1.46% 26
2025
Q1
$14.9M Buy
214,799
+34,048
+19% +$2.44M 1.55% 28
2024
Q4
$12.6M Buy
180,751
+5,773
+3% +$404K 1.3% 35
2024
Q3
$12.4M Buy
174,978
+8,441
+5% +$613K 1.27% 35
2024
Q2
$10.4M Buy
166,537
+3,960
+2% +$351K 1.15% 38
2024
Q1
$14.3M Buy
162,577
+1,867
+1% +$157K 1.66% 29
2023
Q4
$11.7M Buy
160,710
+84,306
+110% +$5.87M 1.46% 33
2023
Q3
$4.71M Buy
76,404
+34,123
+81% +$2.74M 1% 35
2023
Q2
$3.88M Buy
42,281
+18,623
+79% +$1.62M 1% 36
2023
Q1
$2.08M Buy
23,658
+15,287
+183% +$1.2M 0.84% 45
2022
Q4
$650K Buy
+8,371
New +$645K 0.32% 67

Other funds holding EW

Townsend & Associates's EW Position: Q3 2026 in Review

Townsend & Associates increased its Edwards Lifesciences (EW) stake by 1.5% in Q3 2026, buying an estimated $278K and bringing the position to 206,533 shares worth $17.9M. The position accounts for 1.51% of the portfolio, ranked #29.

Townsend & Associates first reported a position in EW in Q4 2022 and has held it in 16 quarters since. 492 funds tracked by Wall St. Rank hold EW as of Q3 2026.

  • Townsend & Associates held 206,533 shares of Edwards Lifesciences worth $17.9M as of Q3 2026.
  • Townsend & Associates bought 3,132 Edwards Lifesciences shares in Q3 2026, an estimated $278K.
  • Edwards Lifesciences made up 1.51% of Townsend & Associates's portfolio in Q3 2026, its #29 holding.
  • Townsend & Associates first reported a position in Edwards Lifesciences in Q4 2022 and has held it in 16 quarters since.
  • 492 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q3 2026.

Based on Townsend & Associates's 13F filing for Q3 2026, filed 23 Oct 2026.